The Danish Company Lundbeck has recently been in the news because of another failed phase III study – and this has caused a steep fall in stocks. What is the problem at Lundbeck?
Lundbeck’s problem is very common amongst research in the psychiatric/neurological field, where placebo has been known to play a very significant role. Similar problems have come up in the research of diseases like ALS and Alzheimer’s, and it is likely due to the great variance between patients, and the fact that we know very little of the brain. Another contributor to the difficulty of research in this field is that animal experiments have historically been very poor in predicting the effect in psychiatric/neurological medicine.
Despite the many problems in doing research, there is a great demand for this field of medicine. Worldwide 350 million people suffer from depression, 21 million from schizophrenia and more than 46 million from dementia. This is why Lundbeck still believes in the future of the field, despite its recent problems.
Read Directing Manager Tove Holm-Larsen’s blog on the subject here (Danish)